Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.6300
-0.0251 (-3.83%)
Mar 31, 2025, 2:26 PM EDT - Market open
Context Therapeutics Stock Forecast
CNTX's stock price has decreased by -52.6% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Context Therapeutics stock have an average target of 6.50, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 931.75% from the current stock price of 0.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Context Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +693.65% | Mar 21, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +1,328.57% | Mar 21, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +1,328.57% | Jan 15, 2025 |
JMP Securities | JMP Securities | Buy Initiates $4 | Buy | Initiates | $4 | +534.92% | Jan 8, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +1,328.57% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
n/a
from 45.36M
Revenue Next Year
n/a
EPS This Year
-0.45
from -0.46
EPS Next Year
-0.54
from -0.45
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.27 | -0.28 | -0.30 | ||
Avg | -0.45 | -0.54 | -0.53 | ||
Low | -0.85 | -0.95 | -0.65 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.